This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The core aim of this proposal is to study the whole-body metabolic processes responsible for hyperglycemia, dyslipidemia adn increased adiposity in patients with schizophrenia or schizoaffective disorder treated with haloperidol, olanzapine, or risperidone in conjunction with valproate
Showing the most recent 10 out of 497 publications